Preoperatively administered ramosetron oral disintegrating tablets for preventing nausea and vomiting associated with patient-controlled analgesia in breast cancer patients.
OBJECTIVE
The purpose of this study was to investigate the acceptability and therapeutic efficacy of a preoperative single administration of long-acting 5-hydroxytryptamine type 3 (5-HT 3) receptor antagonist in an orally disintegrating tablet formulation, ramosetron, in breast cancer patients.


METHODS
Two hundred and forty women, ASA I-II, aged 24-60 yr, undergoing elective breast cancer surgery, were randomized. A standardized anaesthetic technique was used. Patients were assigned to receive one of three treatment regimens (n = 80 in each group): no prophylactic antiemetics (Group A), single prophylactic intravenous injection of ramosetron 0.1 mg at the completion of surgery (Group B) or preoperatively oral administration of 0.1 mg of ramosetron (Group C). Episodes of nausea and vomiting, the use of rescue antiemetic treatment, degree of pain, adverse events and level of satisfaction were recorded.


RESULTS
The overall incidence of nausea and vomiting during the first 24 h after the recovery in Groups B (27.8%) and C (25%) was decreased significantly compared with Group A (75.3%). The frequency of the use of rescue antiemetics was significantly lower in Group C (5.0%) compared with Groups A (53.2%) and B (15.2%). The patients in Group C were more satisfied with control of postoperative nausea and vomiting than others.


CONCLUSIONS
Preoperative oral administration of ramosetron at a dose of 0.1 mg is an acceptable and effective way of reducing the incidence of postoperative nausea and vomiting in breast cancer patients.
Lee
H-J
HJ
Pusan National University, Medical Research Institute, School of Medicine, Department of Anesthesia and Pain Medicine, Busan, Republic of Korea.
Kwon
J-Y
JY
Shin
S-W
SW
Kim
C-H
CH
Baek
S-H
SH
Baik
S-W
SW
Kim
H-K
HK
Kim
K-H
KH
D000284:Administration, Oral; D000328:Adult; D016058:Analgesia, Patient-Controlled / Q000009:adverse effects*; D000701:Analgesics, Opioid / Q000627:therapeutic use; D000932:Antiemetics / Q000008:administration & dosage* / Q000009:adverse effects; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000601:surgery; D005260:Female; D005283:Fentanyl / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D010147:Pain Measurement; D017060:Patient Satisfaction; D020250:Postoperative Nausea and Vomiting / Q000517:prevention & control*; D011292:Premedication; D012702:Serotonin Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D000701:Analgesics, Opioid; D000932:Antiemetics; D001562:Benzimidazoles; D012702:Serotonin Antagonists; C071315:ramosetron; D005283:Fentanyl